Amanta Healthcare IPO 2025 – Complete Detailed Analysis

Allotment Status: CLICK HERE 

 

Amanta Healthcare Limited is set to launch its IPO in September 2025, presenting an investment opportunity in a well-established pharmaceutical formulations company specializing in sterile liquid products. This blog provides a deep dive into the company's profile, IPO specifics, financials, business prospects, risks, and investment rationale, supported by clear tables for clarity.

---

Company Overview

Incorporated in December 1994, Amanta Healthcare Limited is a specialty pharmaceutical company focused primarily on sterile liquid formulations such as injectable drugs, infusion therapy, irrigations, ophthalmic, and respiratory solutions. The company manufactures products mainly under the sterile liquid dosage form category including large volume parenterals (LVP), small volume parenterals (SVP), and specialized solutions using advanced technologies.

Its manufacturing facility is located in Hariyala, Kheda district, Gujarat, India, spread over 66,000 square meters. This WHO-GMP compliant unit employs technologies including advanced blow-fill-seal (ABFS) and isinglass sterile barrier membrane (ISBM) for sterile packaging, ensuring high-quality standards.

Key Company Highlights at a Glance

Parameter	Details
Incorporated	1994
Headquarters	Gujarat, India
Industry	Pharmaceutical Manufacturing (Sterile Liquid Formulations)
Manufacturing Facility	WHO-GMP compliant, located at Hariyala, Kheda, Gujarat
Key Products	Parenteral solutions, fluid therapy, ophthalmic solutions
Technology	Blow-fill-seal, Isinglass Sterile Barrier Membrane (ISBM)
Certifications	WHO-GMP, ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO 45001:2018
Market Reach	Domestic and international markets
Leadership	Experienced management with focus on pharma manufacturing

---

IPO Details

Key IPO Facts

Parameter	Details
IPO Issue Size	1 crore equity shares (~₹126 crore) (Fresh Issue)
Price Band	₹120 to ₹126 per equity share
Face Value	₹10 per share
Minimum Lot Size	119 shares
Minimum Retail Investment	₹14,994 approximately (at upper price band)
IPO Opening Date	September 1, 2025
IPO Closing Date	September 3, 2025
Allotment Date	September 4, 2025
Refund Date	September 8, 2025
Listing Date	September 8, 2025 (BSE & NSE)
Registrar	MUFG Intime India Pvt Ltd
Lead Manager	Beeline Capital Advisors Pvt Ltd
Market Lot	119 shares

The entire IPO is a fresh issue aimed at raising funds to expand the company’s manufacturing capacities.

---

Use of IPO Proceeds

The net proceeds from the IPO will be primarily utilized for the following:

Purpose	Estimated Amount (₹ Crore)	Percentage of Total Proceeds
Setting up New SteriPort Manufacturing Line	₹70 Crore	~55.5%
Setting up New Small Volume Parenterals (SVP) Manufacturing Line	₹30.13 Crore	~24%
General Corporate Purposes	₹25.87 Crore	~20.5%

The infrastructure expansion aims to increase production capacity, enhance technological capabilities, and meet growing market demand for sterile liquid pharmaceuticals.

---

Business Model & Operations

Amanta Healthcare operates a contract manufacturing and marketing model focused on sterile liquid formulations. The company manufactures and distributes products across therapeutic areas such as:

• Fluid therapy and infusion solutions
• Respiratory care products
• Ophthalmic solutions
• Irrigation solutions and diluents

Its advanced manufacturing setup supports large-scale production with high quality and safety standards, fulfilling increasing demand both domestically and in export markets.

---

Financial Overview

Amanta Healthcare has demonstrated stable financial performance with growing revenues and profits supported by manufacturing scale-up and product mix.

Financial Highlights (₹ Crores)

Metric	FY 2025	FY 2024	YoY Growth
Revenue	157.34	140.00	12.39%
EBITDA Margin (%)	16.2%	15.4%	+0.8 pts
Profit After Tax (PAT)	18.4	15.3	20.26%
Earnings Per Share (EPS)	₹14.73	₹12.25	20.24%
Net Worth	100.5	90.0	11.7%

The company’s margin improvement reflects operational efficiency improvements. PAT and EPS growth further enhance investor appeal.

---

Industry Outlook

India’s pharmaceutical manufacturing sector, especially sterile formulations, enjoys strong growth prospects due to:

• Increasing domestic demand and export opportunities.
• Government encouragement for pharmaceutical self-reliance.
• Chronic diseases and acute healthcare needs fueling sterile drug demand.
• Expansion of hospital infrastructure and healthcare awareness.
• Rising adoption of modern sterile drug manufacturing technologies.

Amanta Healthcare’s focus on sterile liquids positions it well to leverage these industry tailwinds.

---

Key Strengths and Competitive Advantages

• WHO-GMP and multiple ISO certifications affirm broad regulatory compliance and quality.
• State-of-the-art manufacturing processes (ABFS, ISBM) ensure sterility and product safety.
• Diversified sterile liquid pharmaceutical portfolio spanning multiple therapeutic segments.
• Large manufacturing campus with capacity to scale as demand grows.
• Experienced leadership and skilled workforce with pharma expertise.
• Positioned to benefit from rising domestic and global demand for sterile formulations.

---

Risks and Challenges

• High dependency on few key customers may impact revenue stability.
• Delays or cost overruns in capacity expansion could affect growth.
• Stringent regulatory environments require ongoing compliance investments.
• Competitive industry with pressures on pricing, margins, and product innovation.
• Exposure to product liability risks inherent to sterile formulations.
• Financial leverage due to IPO proceeds usage requiring prudent management.

---

IPO Application Details

Investor Category	Minimum Bid Qty (Shares)	Minimum Investment (₹) Approx. at Upper Band
Retail Individual Investors	119 shares (1 lot)	₹14,994
Small HNI Investors	1,666 shares (~14 lots)	₹2,09,916
Big HNI Investors	7,973 shares (~67 lots)	₹10,04,598

Applications can be made through ASBA net banking or broker-assisted platforms with bids required within the price band.

---

Summary Table: Amanta Healthcare IPO at a Glance

Feature	Detail
Company	Amanta Healthcare Limited
IPO Type	Book-built Fresh Issue
Issue Size	₹126 Crores
Price Band	₹120 - ₹126 per share
Face Value	₹10
IPO Open Date	September 1, 2025
IPO Close Date	September 3, 2025
Allotment Date	September 4, 2025
Refund Date	September 8, 2025
Listing Date	September 8, 2025 (BSE & NSE)
Minimum Lot Size	119 shares
Minimum Retail Investment	₹14,994
Lead Manager	Beeline Capital Advisors Pvt Ltd
Registrar	MUFG Intime India Pvt Ltd

---

Conclusion: Investment Perspective

Amanta Healthcare’s IPO offers investors a chance to gain exposure to a specialized pharmaceutical player in the fast-growing sterile liquid formulations segment. The company’s robust manufacturing capabilities, strong quality credentials, and significant expansion plans backed by the fresh capital raise create a positive outlook.

Potential investors are encouraged to consider the company’s financial performance, growth strategies, and sector dynamics carefully alongside inherent risks. With its impending listing anticipated in September 2025, this IPO presents an opportunity aligned with India’s pharma growth story and export potential.

---

This detailed and structured coverage should assist investors and pharma sector followers to comprehensively understand the Amanta Healthcare IPO and evaluate it effectively.

[Sources: IPOJi, IPO Platform, Moneycontrol, Zerodha IPO Portal, SMC Global Securities]Here is a comprehensive, blog-style detailed analysis of Amanta Healthcare IPO 2025, with structured tables and all essential information.

---

Amanta Healthcare IPO 2025 – Complete Detailed Analysis

Amanta Healthcare Limited will launch its IPO in September 2025, offering an opportunity to invest in a leading sterile liquid pharmaceutical formulations manufacturer focused on injectable products, infusion therapy, ophthalmic, respiratory, diluents, and irrigation solutions. The company’s WHO-GMP compliant state-of-the-art manufacturing facility is located in Hariyala, Kheda district, Gujarat.

---

Company Overview

Parameter	Details
Incorporation Year	1994
Headquarters	Gujarat, India
Industry	Pharmaceutical Manufacturing (Sterile Liquid Formulations)
Manufacturing Facility	WHO-GMP certified; advanced technologies including Blow-Fill-Seal (ABFS), ISBM
Product Range	Injectable solutions, large and small volume parenterals, fluid therapy, irrigation & ophthalmic
Quality Certifications	WHO-GMP, ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO 45001:2018
Market Presence	Domestic and international markets

---

IPO Details

Parameter	Details
Issue Size	₹126 Crore (Fresh Issue of 1 crore shares)
Price Band	₹120 – ₹126 per equity share
Face Value	₹10 per share
Minimum Lot Size	119 shares
Minimum Investment (Retail)	Approx. ₹14,994 (at upper band)
IPO Opening Date	September 1, 2025
IPO Closing Date	September 3, 2025
Allotment Date	September 4, 2025
Refund Date	September 8, 2025
Listing Date	September 8, 2025 (BSE and NSE)
Registrar	MUFG Intime India Pvt Ltd
Lead Manager	Beeline Capital Advisors Pvt Ltd

---

Use of IPO Proceeds

Purpose	Estimated Amount (₹ Crore)	Percentage of Total Proceeds
New SteriPort Manufacturing Line Setup	₹70 Crore	55.5%
New Small Volume Parenterals (SVP) Line	₹30.13 Crore	24%
General Corporate Purposes	₹25.87 Crore	20.5%

---

Business Model and Operations

Amanta Healthcare specializes in sterile liquid formulations manufacturing with focus on:

• Injectable solutions and infusion therapies.
• Ophthalmic, respiratory, diluent, and irrigation solutions.
• Utilizing advanced sterile technologies for safety and quality.
• Contract manufacturing and own branded distribution channels.

---

Financial Summary (₹ Crore)

Metric	FY 2025	FY 2024	YoY Growth
Revenue	157.34	140.00	12.39%
EBITDA Margin (%)	16.2%	15.4%	+0.8 pts
Profit After Tax (PAT)	18.4	15.3	20.26%
Earnings Per Share (EPS)	₹14.73	₹12.25	20.24%
Net Worth	100.5	90.0	11.7%

---

Industry Outlook

• Increasing demand for sterile injectables driven by rise in chronic diseases and healthcare access.
• Government initiatives supporting pharmaceutical manufacturing (Make in India).
• Expansion of export markets for sterile liquid formulations.
• Growth of hospital infrastructure and clinical treatments requiring sterile medicines.
• Technological advancements enhancing manufacturing efficiency and safety compliance.

---

Strengths and Competitive Advantages

• WHO-GMP and multiple ISO certifications ensuring high-quality standards.
• Advanced sterile formulation manufacturing facility with ABFS and ISBM technology.
• Diversified product portfolio with focus on high-demand sterile liquids.
• Experienced leadership and skilled workforce.
• Strong position in domestic and international pharmaceutical markets.

---

Risks and Challenges

• Dependence on a limited number of major customers.
• Regulatory and product liability risks inherent in sterile pharma products.
• Risks related to delays or cost overruns in manufacturing expansion.
• Pricing and margin pressures from competition.
• Requirement of continuous compliance with stringent industry norms.

---

Application Details

Investor Category	Minimum Bid Qty (Shares)	Minimum Investment (₹ Approx.) at Upper Band
Retail Individual	119 shares (1 lot)	₹14,994
Small HNI	1,666 shares (~14 lots)	₹2,09,916
Big HNI	7,973 shares (~67 lots)	₹10,04,598

---

IPO Timeline

Event	Date
IPO Open Date	September 1, 2025
IPO Close Date	September 3, 2025
Allotment Date	September 4, 2025
Refund Date	September 8, 2025
Listing Date	September 8, 2025
Lock-in Period End Date	October 4, 2025 (Anchor Investors - 50%)
	December 3, 2026 (Anchor Investors - remaining 50%)

---

Summary Table: Amanta Healthcare IPO Overview

Feature	Detail
Company	Amanta Healthcare Limited
IPO Size	₹126 Crore (Fresh Issue)
Price Band	₹120 – ₹126
Face Value	₹10
Minimum Lot Size	119 shares
Opening Date	September 1, 2025
Closing Date	September 3, 2025
Allotment Date	September 4, 2025
Refund Date	September 8, 2025
Listing Date	September 8, 2025
Registrar	MUFG Intime India Pvt Ltd
Lead Manager	Beeline Capital Advisors Pvt Ltd

---

Conclusion

Amanta Healthcare IPO is an opportunity to invest in a well-established, WHO-GMP certified pharma manufacturing firm with strong growth potential in sterile liquid formulations sector. Backed by advanced manufacturing tech, diverse product lines, and sound financials, the company is well placed to leverage growing global and domestic demand for sterile injectable products.

Potential investors should evaluate the company’s growth prospects alongside risks like customer concentration and regulatory factors. This IPO suits those interested in pharmaceutical manufacturing with mid-to-long-term investment horizons.